# ALLOX Closes $10.5 million Seed Round Led by Asabys and Names Morten Graugaard Chair

> ALLOX closed a $10.5 million seed round led by Asabys to scale its allosteric drug discovery platform and named Morten Graugaard independent chair of its board.

- Published: 2026-10-29T09:19:32+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-29/allox-seed-round-asabys-graugaard-chair
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/29/3390985/0/en/allox-closes-10-5m-seed-financing-and-appoints-morten-graugaard-as-chair-to-scale-allosteric-drug-discovery-platform-and-build-pipeline.html)

## Key takeaways

- ALLOX closed a US$10.5m (€9.4m) seed round led by Asabys through its Sabadell Asabys II fund.
- CDTI with its SICC Innvierte and the Institut Català de Finances participated in the round.
- Morten Graugaard, Co-founder and CBO of Orbis Medicines, was appointed Independent Chair of ALLOX's Board of Directors.

ALLOX closed a US$10.5m (€9.4m) seed financing round led by Asabys through its Sabadell Asabys II fund, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF), the company said in a [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/29/3390985/0/en/allox-closes-10-5m-seed-financing-and-appoints-morten-graugaard-as-chair-to-scale-allosteric-drug-discovery-platform-and-build-pipeline.html) announcement on October 29, 2026. The Barcelona-based biotechnology company also appointed Morten Graugaard as Independent Chair of its Board of Directors.

## ALLOX's Seed Round and Platform Plans

[ALLOX](https://akta.pro/company-profiles/00qpjl1/allox) said proceeds will scale and expand its high-throughput biophysics and AI drug discovery platform and fund proprietary AI models that predict therapeutic hotspots from its function-first biophysical datasets. The financing will also strengthen its internal drug discovery team as it advances multiple programs toward a focused pipeline of proprietary small-molecule assets and enables research collaborations with pharmaceutical and biotechnology partners.

Júlia Domingo, Chief Executive Officer and Co-Founder of ALLOX, said: "This financing marks an important milestone, enabling us to advance our internal drug discovery pipeline while expanding the capabilities of our experimental platform and proprietary AI models."

Graugaard brings more than 20 years of experience across life sciences venture investing, R&D, business development and M&A. He is currently Chief Business Officer of Orbis Medicines and previously was a Partner and Investment Director at Novo Holdings. As Director of Corporate Development at Lundbeck A/S, he led the company's US$658 million acquisition of Chelsea Therapeutics and was a key member of the deal team that negotiated a US$1.8 billion global alliance with Otsuka Pharmaceutical.

Clara Campàs, Co-Founder and Managing Partner at [Asabys Partners](https://akta.pro/company-profiles/00000nj/asabys-partners), said: "We believe ALLOX is uniquely positioned to expand the scope of druggable biology." Asabys is a Barcelona-based venture capital firm with over €400 million in AUM and 24 portfolio companies, supported by Alantra and backed by Banc Sabadell as anchor investor. The investment was made through Sabadell Asabys Health Innovation Investments II, FCR, and Sabadell Asabys Health Innovation Investments 2B, SCR, S.A., with support from the European Union under the InvestEU Fund through the European Investment Fund.

## ALLOX's Funding History and Team Buildout

According to akta.pro [company records](https://akta.pro/company-data), ALLOX has two funding rounds on record: a 2023-12 pre-seed led by Asabys Partners and a 2026-07 seed led by CDTI Innovación's INNVIERTE program. The same records list ALLOX as founded in 2023, headquartered in Barcelona with a headcount range of 11-50, and pre-revenue.

The records also show ALLOX hired Grzegorz Chojnowski (ex-EMBL Hamburg) as Senior R&D Computational Scientist and Andrei Papkou (ex-University of Zurich) as Platform Bioinformatician in 2025-10, and posted open roles for Chief Scientific Officer and Senior AI Scientist – Protein Function & Drug Discovery with start dates in July 2026.

## ALLOX's Next Steps After the Seed Round

ALLOX said the financing will strengthen its internal drug discovery team as it advances multiple drug discovery programs toward a focused pipeline of proprietary small-molecule assets. The company said the proceeds will also enable strategic research collaborations with pharmaceutical and biotechnology partners.

## Companies in this story

- [ALLOX company profile](https://akta.pro/company-profiles/00qpjl1/allox) · website: https://www.allox.bio
- [Asabys Partners company profile](https://akta.pro/company-profiles/00000nj/asabys-partners) · website: https://asabys.com
- [Centre for the Development of Industrial Technology (CDTI) company profile](https://akta.pro/company-profiles/00024af/centre-for-the-development-of-industrial-technology-cdti) · website: http://www.cdti.es

---
News for Agent · https://newsforagent.com/llms.txt